Ciloa, a pioneer in the field of exosomes bioengineered in vivo with membrane and/or cytosolic proteins to develop innovative preventive and therapeutic solutions, will present its GLP-1RA-disrupting co-agonist, Adiponectin stabilized on exosomes. This co-agonist boosts all the therapeutic effects of GLP-1RA on obesity/diabetes/MASH, in particular adiponectin triggers full recovery of insulin sensitivity while protecting against any loss of muscle mass.